AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37729613 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without positive tests
Number of subjects: 503
Study 37729613 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who tested positive for COVID-19
Number of subjects: 503
Study 37729613 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low normal B cells after recent treatment
Number of subjects: 503
Study 37729613 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort of patients with HCL/HCLv
Number of subjects: 503
Study 37729663 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 50 mg/day for 8 weeks
Number of subjects: 95
Study 37729663 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 225 mg/day for 8 weeks
Number of subjects: 95
Study 37729663 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric comorbidity
Number of subjects: 95
Study 37729887 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide (ETL)
Number of subjects: 62
Study 37729887 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (ALFA)
Number of subjects: 62
Study 37729939 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Number of subjects: 0
Study 37729939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Number of subjects: 0
Study 37729939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 0
Study 37729939 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with curcumin, ginkgolide B, saponins, vitamin E, niacinamide, or triptolide
Number of subjects: 0
Study 37729939 — intervention group
Group type: EXPERIMENTAL
Intervention: β-hydroxybutyrate supplements
Number of subjects: 0
Study 37729939 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary guidelines
Number of subjects: 0
Study 37730089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 150 mg every 4 weeks (Q4W) for patients aged 2 to <6 years
Number of subjects: 21
Study 37730089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 150 mg every 2 weeks (Q2W) for patients aged 6 to <12 years
Number of subjects: 21
Study 37730089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab (both Q2W and Q4W regimens)
Number of subjects: 21
Study 37730193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 382
Study 37730193 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Steady-State (MISS) Training
Number of subjects: 382
Study 37730193 — intervention group
Group type: COMPARATOR
Intervention: HIIT vs MISS
Number of subjects: 382
Study 37730196 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine taper with cognitive behavioral therapy (BZT + CBT)
Number of subjects: 54
Study 37730196 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine taper with health education program (BZT + HE)
Number of subjects: 54
Study 37730197 — intervention group
Group type: EXPERIMENTAL
Intervention: Five highly disseminable and sustainable cessation components in a factorial experiment
Number of subjects: 0
Study 37730199 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored exercise prescription (aerobic and strengthening components) supervised remotely by fitness professionals over 20 weeks
Number of subjects: 160
Study 37730199 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (details not specified)
Number of subjects: 160
Study 37730252 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative evaluation of endothelial viability using trypan blue staining and custom image analysis
Number of subjects: 0
Study 37730386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS) for 7 days, twice daily for 30 minutes
Number of subjects: 116
Study 37730386 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 7 days, twice daily for 30 minutes
Number of subjects: 116
Study 37730392 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application-based rehabilitation for 12 weeks
Number of subjects: 162
Study 37730392 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient medical treatment without rehabilitation
Number of subjects: 162
Study 37730397 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Aids (CDAs) including those that use procalcitonin testing
Number of subjects: 0
Study 37730397 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency clinical care
Number of subjects: 0
Study 37730403 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque Teno Virus (TTV) levels measured using the TTV R-GENE kit
Number of subjects: 172
Study 37730403 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV levels
Number of subjects: 172
Study 37730405 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with erythrosine and blue light (LED)
Number of subjects: 30
Study 37730405 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 30
Study 37730415 — intervention group
Group type: EXPERIMENTAL
Intervention: Last Menstrual Period (LMP)
Number of subjects: 42803
Study 37730415 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography (USG)
Number of subjects: 42803
Study 37730501 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/wk for 24 weeks
Number of subjects: 12
Study 37730530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (60 min during the second hour of thrice weekly dialysis for 6 months)
Number of subjects: 44
Study 37730530 — intervention group
Group type: COMPARATOR
Intervention: No intradialytic exercise
Number of subjects: 44
Study 37730561 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic intervention procedure involving collaboration between GPs, RCs, and employers
Number of subjects: 112
Study 37730561 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 112
Study 37730613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile tea (3 tea bags × 3 times daily)
Number of subjects: 12
Study 37730613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract capsule (3 times daily)
Number of subjects: 12
Study 37730613 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule (3 times daily)
Number of subjects: 12
Study 37730613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile tea
Number of subjects: 12
Study 37730613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract capsule
Number of subjects: 12
Study 37730613 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 12
Study 37730614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirtuin1 (SIRT1)
Number of subjects: 52
Study 37730614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide phosphoribosyl transferase (NAMPT)
Number of subjects: 52
Study 37730614 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT1
Number of subjects: 52
Study 37730614 — intervention group
Group type: EXPERIMENTAL
Intervention: NAMPT
Number of subjects: 52
Study 37730614 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT1 and NAMPT
Number of subjects: 52
Study 37730674 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transcriptional gene silencing of BCL11A expression (gene therapy)
Number of subjects: 9
Study 37730674 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 9
Study 37730689 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 95
Study 37730689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 37730732 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Aminovaleric acid betaine (5-AVAB) serum levels
Number of subjects: 143
Study 37730833 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC-based nasal spray solution containing human IgG1 antibodies against SARS-CoV-2
Number of subjects: 0
Study 37730963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy (8 sessions)
Number of subjects: 100
Study 37730990 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subcallosal cingulate (SCC)
Number of subjects: 0
Study 37731023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nofazinlimab monotherapy (200 mg Q3W)
Number of subjects: 122
Study 37731023 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib plus nofazinlimab (400 mg Q6W and 200 mg Q3W)
Number of subjects: 122
Study 37731023 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib plus nofazinlimab (part 2a)
Number of subjects: 122
Study 37731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 3000 mg to W4 then 600 mg q4w
Number of subjects: 152
Study 37731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 3000 mg to W4 then 300 mg q4w
Number of subjects: 152
Study 37731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 1500 mg to W4 then 600 mg q4w
Number of subjects: 152
Study 37731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 1500 mg to W4, 300 mg q4w to W16 then 300 mg q8w
Number of subjects: 152
Study 37731086 — intervention group
Group type: COMPARATOR
Intervention: Placebo switching to spesolimab 600 mg q4w at W16
Number of subjects: 152
Study 37731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spesolimab groups
Number of subjects: 152
Study 37731086 — intervention group
Group type: COMPARATOR
Intervention: Placebo switch to spesolimab
Number of subjects: 152
Study 37731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab in non-Asian patients
Number of subjects: 152
Study 37731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab and placebo
Number of subjects: 152
Study 37731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab
Number of subjects: 152
Study 37731137 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone call reminder
Number of subjects: 2658
Study 37731137 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text message reminder
Number of subjects: 2658
Study 37731137 — intervention group
Group type: COMPARATOR
Intervention: Control (no reminder)
Number of subjects: 2658
Study 37731394 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lipid and metabolic markers (including HDL, triglycerides, glucose)
Number of subjects: 71
Study 37731394 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lipid and metabolic markers
Number of subjects: 71
Study 37731394 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy BMI and maternal age
Number of subjects: 71
Study 37731489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel (DOS-CP)
Number of subjects: 0
Study 37731489 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel (PLB-CP)
Number of subjects: 0
Study 37731491 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 inhibitor
Number of subjects: 0
Study 37731491 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 37731526 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen type 1 N-terminal Propeptide (P1NP) quartiles
Number of subjects: 813
Study 37731529 — intervention group
Group type: EXPERIMENTAL
Intervention: SVT-triggered CS patients
Number of subjects: 769
Study 37731529 — intervention group
Group type: COMPARATOR
Intervention: Non-SVT-triggered CS patients
Number of subjects: 769
Study 37731709 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality combined with standard physiotherapy
Number of subjects: 0
Study 37731709 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 0
Study 37731709 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention
Number of subjects: 0
Study 37731785 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus enhanced community doula support
Number of subjects: 367
Study 37731785 — intervention group
Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 367
Study 37731785 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced community doula support
Number of subjects: 367
Study 37731938 — intervention group
Group type: COMPARATOR
Intervention: BBBIP-CorV
Number of subjects: 1351
Study 37731938 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTV01C
Number of subjects: 1351
Study 37731938 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTV01E
Number of subjects: 1351
Study 37732075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom Power intervention (10 group sessions and 3 individual sessions)
Number of subjects: 122
Study 37732075 — intervention group
Group type: COMPARATOR
Intervention: Control group (psychoeducational mailings)
Number of subjects: 122
Study 37732075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom Power intervention
Number of subjects: 122
Study 37732080 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 to 200 mg/day)
Number of subjects: 12
Study 37732080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 37732489 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized blood pressure management strategy targeting intraprocedural SBP to preinterventional baseline values.
Number of subjects: 250
Study 37732489 — intervention group
Group type: COMPARATOR
Intervention: Standardized blood pressure management aiming to maintain intraprocedural SBP between 140 and 180 mm Hg.
Number of subjects: 250
Study 37732496 — intervention group
Group type: EXPERIMENTAL
Intervention: LULs >20 mm
Number of subjects: 1073
Study 37732496 — intervention group
Group type: EXPERIMENTAL
Intervention: LULs 16-20 mm
Number of subjects: 1073
Study 37732496 — intervention group
Group type: COMPARATOR
Intervention: Baseline screening and follow-up
Number of subjects: 1073
Study 37732619 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lithium treatment
Number of subjects: 0
Study 37732619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37732745 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical clipping of UIA (benchmark cohort)
Number of subjects: 2245
Study 37732786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanshinone I
Number of subjects: 0
Study 37732786 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37732961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts-extended release (MAS-ER) 80 mg/day for 10 weeks
Number of subjects: 145
Study 37732961 — intervention group
Group type: COMPARATOR
Intervention: Placebo 80 mg/day for 10 weeks
Number of subjects: 145
Study 37732961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts-extended release (MAS-ER)
Number of subjects: 145
Study 37732961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 37732972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Lifters for Graduate Students (ML-GS)
Number of subjects: 131
Study 37732972 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 131
Study 37732990 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 3 mg
Number of subjects: 160
Study 37732990 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 1 mg
Number of subjects: 160
Study 37732990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 37733083 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesix™ mesh
Number of subjects: 270
Study 37733083 — intervention group
Group type: EXPERIMENTAL
Intervention: Progrip™ mesh
Number of subjects: 270
Study 37733159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.8 mmol/L, 50 mg/dL) during PM clamp
Number of subjects: 16
Study 37733159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.8 mmol/L, 50 mg/dL) during AM clamp
Number of subjects: 16
Study 37733159 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16
Study 37733159 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels
Number of subjects: 16
Study 37733189 — intervention group
Group type: EXPERIMENTAL
Intervention: Full RHC intervention
Number of subjects: 169
Study 37733189 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study 37733309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 110
Study 37733309 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 110
Study 37733308 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (200 μg once daily for 14 days)
Number of subjects: 1407
Study 37733308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1407
Study 37733308 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate
Number of subjects: 1407
Study 37733308 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate and Placebo
Number of subjects: 1407
Study 37733345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower hemoglobin threshold group
Number of subjects: 179
Study 37733345 — intervention group
Group type: COMPARATOR
Intervention: Higher hemoglobin threshold group
Number of subjects: 179
Study 37733345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study 37733345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransfusion Csat less than 50%
Number of subjects: 179
Study 37733356 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 68
Study 37733356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 37733364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 1405
Study 37733364 — intervention group
Group type: COMPARATOR
Intervention: No axillary surgery
Number of subjects: 1405
Study 37733364 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB
Number of subjects: 1405
Study 37733479 — intervention group
Group type: EXPERIMENTAL
Intervention: iCC-SCD (digital cognitive-behavioral therapy program)
Number of subjects: 137
Study 37733479 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 137
Study 37733487 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session telephone-delivered intervention to increase patient activation
Number of subjects: 250
Study 37733487 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 250
Study 37733666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine flux with varying forms (freebase vs protonated) in Trial I
Number of subjects: 0
Study 37733666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine flux with varying forms in Trial II
Number of subjects: 0
Study 37733724 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated mumps vaccine
Number of subjects: 10057
Study 37733966 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.25% ophthalmic suspension, 4 times daily for 2 months, tapered to once daily for 10 months
Number of subjects: 70
Study 37733966 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.25% ophthalmic suspension
Number of subjects: 70
Study 37733966 — intervention group
Group type: COMPARATOR
Intervention: Historical data (loteprednol 0.5% gel)
Number of subjects: 70
Study 37733966 — intervention group
Group type: COMPARATOR
Intervention: Historical data (prednisolone 1% suspension)
Number of subjects: 70
Study 37733977 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone (AAP) with concomitant stereotactic body radiation therapy (SBRT)
Number of subjects: 157
Study 37733977 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate and prednisone (AAP) alone
Number of subjects: 157
Study 37733980 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Education (VE)
Number of subjects: 662
Study 37733980 — intervention group
Group type: COMPARATOR
Intervention: Genetic Counseling (GC)
Number of subjects: 662
Study 37733980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VE and GC
Number of subjects: 662
Study 37733984 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom monitoring with electronic patient-reported outcomes (ePROs) via smartphone app
Number of subjects: 250
Study 37733984 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom monitoring with ePROs
Number of subjects: 250
Study 37733984 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET)
Number of subjects: 250
Study 37734031 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37734091 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 197
Study 37734091 — intervention group
Group type: COMPARATOR
Intervention: In-office surveillance
Number of subjects: 197
Study 37734093 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of H.E.A.R.T RCT
Number of subjects: 38
Study 37734293 — intervention group
Group type: EXPERIMENTAL
Intervention: CORALYS HF score
Number of subjects: 14699
Study 37734293 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning analysis
Number of subjects: 14699
Study 37734399 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (three preoperative and three postoperative 3-week cycles of intravenous 50 mg/m² epirubicin plus cisplatin or oxaliplatin plus fluorouracil or capecitabine or FLOT)
Number of subjects: 362
Study 37734399 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen])
Number of subjects: 362
Study 37734804 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill regimen (5 mg ramipril, 50 mg atenolol, 12.5 mg hydrochlorothiazide, 20 mg simvastatin, 100 mg aspirin administered as two capsules once per day for 12 months)
Number of subjects: 148
Study 37734804 — intervention group
Group type: COMPARATOR
Intervention: Usual care (tailored guideline-recommended secondary prevention medications)
Number of subjects: 148
Study 37734804 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study 37734804 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill regimen
Number of subjects: 148
Study 37734837 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-driven consolidative strategy
Number of subjects: 0